Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.5.4 was added to the page, replacing the previous v3.5.3. This represents a small metadata update indicating a new publication revision.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s footer revision/version number has been updated from v3.5.2 to v3.5.3, indicating a site release or template update without substantive changes to the clinical trial information.SummaryDifference0.0%

- Check43 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check57 days agoChange DetectedAdministrative metadata such as last update dates and submission history was refreshed; no core study details, eligibility criteria, or outcomes appear to have changed.SummaryDifference0.2%

- Check71 days agoChange DetectedA new page revision label v3.5.0 was added, replacing the previous v3.4.3.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.